Loading...
XNAS
VRTX
Market cap121bUSD
Apr 04, Last price  
474.62USD
1D
-1.94%
1Q
16.58%
Jan 2017
544.25%
Name

Vertex Pharmaceuticals Inc

Chart & Performance

D1W1MN
XNAS:VRTX chart
No data to show
P/E
—
P/S
11.06
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-0.21%
Rev. gr., 5y
21.50%
Revenues
11.02b
+11.66%
160,890,000216,356,000199,012,000175,504,000102,049,000143,370,0001,410,626,0001,527,042,0001,211,975,000580,415,0001,032,336,0001,702,177,0002,488,652,0003,047,597,0004,162,821,0006,205,683,0007,574,400,0008,930,700,0009,869,200,00011,020,100,000
Net income
-536m
L
-203,417,000-206,891,000-391,279,000-459,851,000-641,578,000-754,626,00029,574,000-107,032,000-445,028,000-738,555,000-558,115,000-112,052,000263,484,0002,096,896,0001,176,810,0002,711,700,0002,342,100,0003,322,000,0003,619,600,000-535,600,000
CFO
-493m
L
-172,054,000-22,475,000-252,476,000-226,482,000-427,586,000-635,442,000143,735,000267,841,000-51,570,000-513,199,000-365,432,000236,103,000844,942,0001,270,286,0001,569,330,0003,253,505,0002,643,500,0004,129,900,0003,537,300,000-492,600,000
Earnings
May 05, 2025

Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
URL
https://www.vrtx.com/
IPO date
Jul 24, 1991
Employees
4,800
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,020,100
11.66%
9,869,200
10.51%
8,930,700
17.91%
Cost of revenue
5,160,800
4,425,100
3,620,600
Unusual Expense (Income)
NOPBT
5,859,300
5,444,100
5,310,100
NOPBT Margin
53.17%
55.16%
59.46%
Operating Taxes
784,100
760,200
910,400
Tax Rate
13.38%
13.96%
17.14%
NOPAT
5,075,200
4,683,900
4,399,700
Net income
(535,600)
-114.80%
3,619,600
8.96%
3,322,000
41.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,582,100)
(293,000)
14,300
BB yield
1.52%
0.28%
-0.02%
Debt
Debt current
92,300
83,700
89,400
Long-term debt
3,406,700
2,174,100
943,200
Deferred revenue
Other long-term liabilities
901,800
153,000
1,336,000
Net debt
(7,724,800)
(11,556,900)
(9,845,300)
Cash flow
Cash from operating activities
(492,600)
3,537,300
4,129,900
CAPEX
(297,700)
(200,400)
(204,700)
Cash from investing activities
(3,770,000)
(3,141,700)
(321,100)
Cash from financing activities
(1,494,900)
(562,200)
(67,700)
FCF
3,774,200
4,339,400
4,385,400
Balance
Cash
6,115,900
11,218,300
10,778,500
Long term investments
5,107,900
2,596,400
99,400
Excess cash
10,672,795
13,321,240
10,431,365
Stockholders' equity
9,737,200
10,130,700
6,526,200
Invested Capital
9,323,700
9,135,800
9,160,200
ROIC
54.99%
51.20%
50.76%
ROCE
30.74%
28.26%
33.85%
EV
Common stock shares outstanding
257,900
260,500
259,100
Price
402.70
-1.03%
406.89
40.90%
288.78
31.50%
Market cap
103,856,330
-2.02%
105,994,845
41.66%
74,822,898
31.10%
EV
96,131,530
94,437,945
64,977,598
EBITDA
6,066,500
5,625,400
5,458,400
EV/EBITDA
15.85
16.79
11.90
Interest
30,600
44,100
54,800
Interest/NOPBT
0.52%
0.81%
1.03%